Update: We revised this post on Feb. 25 based on community feedback we received.
ProPublica is spending the year examining out-of-reach care for hundreds of thousands, if not millions, of people across the country with Type 1 and 2 diabetes. We need your help to understand how the cost of care is threatening lives.
We know that the cost of insulin has been in the news a lot recently. That’s largely because in the past decade, the price of insulin has tripled, and some people are rationing their own stock. In extreme cases, people are dying because they cannot get access to a regular supply.
We want to dig deeper. How has access to supplies affected your health? How has having diabetes affected your career? What roles do insurers play in the price of your treatment?
We’ve seen remarkable innovation around diabetes care, but in the past decade, the progress we had made on patient outcomes has reversed course. Help us figure out what that means for people with diabetes by sharing your story or expertise with us below. We’re particularly interested in hearing the stories of people who have faced diabetic ketoacidosis, those who have gone into diabetic comas and those who have passed away. We’re also interested in hearing the stories of people who have suffered heart attacks and heart failure, strokes and other life-threatening complications.